Treatment of agnogenic myeloid metaplasia with danazol: A report of four cases

In: American Journal of Hematology · 1996 · vol. 53(4) , pp. 239–241 · doi:10.1002/(sici)1096-8652(199612)53:4<239::aid-ajh5>3.0.co;2-z · PMID:8948661 · W2017709151
article OA: closed CC0 ⤵ 5 in-corpus citations
AI-generated summary by claude@2026-06, 2026-06-08

Four patients with agnogenic myeloid metaplasia and severe cytopenia treated with danazol showed improved red blood cell transfusion independence, with some patients experiencing corrected thrombocytopenia and reduced splenomegaly.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Peripheral cytopenias are common in patients with agnogenic myeloid metaplasia (AMM). They are an important cause of morbidity and mortality, and their treatment is difficult. We report on 4 patients with AMM and severe cytopenia treated with danazol (400-600 mg/ day). Three of them became independent of red blood cell (RBC) transfusion, while the other had a slight reduction in RBC requirement. In addition, correction of thrombocytopenia and disappearance of splenomegaly were observed in 1 and 2 patients, respectively. No side effects were observed. In our experience, danazol appears effective and safe in the subset of patients with AMM whose disease is mainly characterized by bone-marrow failure. These data warrant further studies to evaluate this treatment and explore its mechanism of action.

My notes (saved in your browser only)

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (10)

Cited by (5)

Source provenance

openalex
last seen: 2026-05-11T05:39:31.692385+00:00
unpaywall
last seen: 2026-05-23T02:00:01.238055+00:00
License: CC0 · commercial use OK